Table 2

Determinants of spontaneous clearance of NG in patients with an NG infection at the pre-enrolment visit: results of the univariable and multivariable logistic regression analyses, NABOGO trial, Amsterdam, the Netherlands, from 18 September 2017 to 5 June 2020

Univariable logistic regressionMultivariable logistic regression
OR95% CIP valueaOR95% CIP value
Time (in days) between T−1 and T01.071.02 to 1.120.0041.061.01 to 1.120.011
Age, per 10-year increase0.910.69 to 1.190.477
Age (years)
 30–390.600.30 to 1.200.680.33 to 1.400.297
 ≥400.640.32 to to 2.350.933
Gender identity
 Female or transgender2.550.98 to 6.65
 Non-Dutch1.070.59 to 1.96
Highest education level
 College/university1.460.66 to 3.21
 Other1.190.32 to 4.45
HIV status
 HIV-negative+no PrEP userREF0.132REF
 HIV-negative+PrEP user0.470.22 to 0.980.530.24 to 1.160.101
 HIV-positive0.810.37 to 1.780.800.31 to 2.020.630
Antibiotic use*
 Yes1.170.50 to 2.72
Location of NG infection
 Anal0.690.37 to 1.260.630.32 to 1.250.189
 Vaginal1.240.31 to 4.900.280.03 to 2.500.255
 Urethral1.760.69 to 4.511.660.59 to 4.670.339
Sexual behaviour
Sexual risk group
 MSW, women, TGP2.210.87 to 5.66
Number of sexual partners†‡0.600.43 to 0.840.003
Number of sexual partners, in tertiles
 6–150.290.14 to 0.580.280.13 to 0.590.001
 ≥160.480.24 to 0.940.550.25 to 1.200.135
  • Time between T−1 and T0, age, gender identity, HIV status, location of NG infection, sexual risk group and number of sexual contacts in the preceding 6 months before T−1 were included in the initial multivariable model before backwards selection.

  • *In the preceding 3 months before T−1.

  • †In the preceding 6 months before T−1.

  • ‡OR per (log+1) increase in number of sexual partners.

  • aOR, adjusted OR; MSM, men who have sex with men; MSW, men who have sex with women; NABOGO, New AntiBiotic treatment Options for uncomplicated Gonorrhoea; NG, Neisseria gonorrhoeae; PrEP, pre-exposure prophylaxis; REF, reference; TGP, transgender people.